تخطي إلى التنقل الرئيسي
تخطي إلى البحث
تخطي إلى المحتوى الرئيسي
الصفحة الرئيسية
المساعدة والأسئلة الشائعة
English
עברית
العربية
الصفحة الرئيسية
الملفات الشخصية
الوحدات البحثية
نتاج البحث
الجوائز
أنشطة
البحث حسب الخبرة أو الاسم أو الانتماء
عرض الملف الشخصي الخاص بـ Scopus
נתן קלר
Prof.
Associate Professor
,
Department of Health Systems Management
https://orcid.org/0000-0001-5351-4150
1989 …
2024
نتاج الأبحاث سنويًا
معاينة
بصمة
الشبكة
نتاج البحث
(151)
ملفات شخصية مماثلة
(6)
بصمة
تأتي تسميات الموضوعات هذه من أعمال هذا الشخص. فهما يشكلان معًا بصمة فريدة.
فرز حسب
الوزن
أبجديًا
Keyphrases
Israel
100%
Antibiotics
35%
Risk Factors
32%
Escherichia Coli
29%
Invasive Pneumococcal Disease
28%
Fluconazole
27%
Staphylococcus Aureus
25%
Artemis
24%
Hospitalized Patients
24%
Tertiary Care Hospital
23%
Bacteremia
23%
Surveillance Program
22%
Ciprofloxacin
21%
Candida
20%
Neisseria Meningitidis
18%
Bloodstream Infection
17%
Voriconazole
17%
Endocarditis
17%
Temporal Trends
16%
Geographic Trends
16%
Cardiopulmonary Bypass
16%
Clinical Characteristics
16%
Medical Center
15%
Israeli
15%
Helicobacter Pylori (H. pylori)
15%
Surveillance Studies
15%
Pediatric Patients
15%
Group A Streptococcus
14%
Serogroup B
14%
Klebsiella Pneumoniae (K. pneumoniae)
14%
Antimicrobial Resistance
14%
Minimum Inhibitory Concentration
13%
Quantitative PCR
13%
Ceftriaxone
13%
Streptococcus Pneumoniae
13%
Disc Diffusion
13%
Penicillin
12%
Postoperative Course
12%
Epidemiology
12%
Vancomycin-intermediate Staphylococcus Aureus
12%
Stenotrophomonas Maltophilia
12%
Rapid Detection
12%
Successful Treatment
12%
Methicillin-resistant S. Aureus
12%
Pseudomonas Aeruginosa (P. aeruginosa)
12%
KPC-2
12%
Blood Isolates
12%
S. Pneumoniae
12%
Antimicrobial
11%
Immunocompromised Patients
11%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
73%
Bloodstream Infection
46%
Diseases
32%
Staphylococcus Aureus
29%
Prevalence
22%
Antimicrobial Resistance
21%
Antibiotics
19%
Antiinfective Agent
18%
Infectious Agent
17%
Ciprofloxacin
15%
Escherichia coli
15%
Candida
15%
Mortality Rate
15%
Meticillin
14%
Fluconazole
13%
Vancomycin Intermediate Staphylococcus Aureus
12%
Mucormycosis
12%
SARS Coronavirus
12%
Penicillin
11%
Sepsis
11%
Amoxicillin
10%
Streptococcus Group A
10%
Candidemia
10%
Vancomycin
10%
Endocarditis
9%
Pseudomonas aeruginosa
9%
Staphylococcal Bacteremia
8%
Blood Clotting Factor 8
8%
Quinolone Derivative
8%
Pharmacokinetics
8%
Carbapenem
8%
Stenotrophomonas maltophilia
8%
Pneumococcal Infection
8%
Salmonella
8%
Extended Spectrum Beta Lactamase
7%
Immunocompromised Patient
7%
Penicillinase
7%
Cefepime
7%
Methicillin-Resistant Staphylococcus Aureus
7%
Antibiotic Therapy
7%
Coronavirinae
6%
Klebsiella pneumoniae
6%
Streptococcus Pneumonia
6%
Clarithromycin
5%
Respiratory Virus
5%
RNA 16S
5%
Enterococcus
5%
Helicobacter Pylori
5%
Cohort Study
5%
Respiratory Tract Infection
5%
Medicine and Dentistry
Infection
78%
Serotype
27%
Diseases
25%
Bloodstream Infection
22%
Pathogen
21%
Meningococcal Disease
20%
Cardiopulmonary Bypass
16%
Cohort Effect
14%
Neisseria meningitidis
13%
Intensive Care Unit
12%
Mucormycosis
12%
Stenotrophomonas maltophilia
12%
Endocarditis
12%
Bypass in Children
12%
Antibiotic Resistance
12%
Staphylococcus Aureus
11%
Influenza A Virus (H3N2)
11%
Sepsis
11%
Mortality Rate
10%
Toddlers
10%
Immunocompromised Patient
9%
Pediatrics
8%
Pneumococcal Infection
8%
Neonatal Sepsis
8%
Continuous Infusion
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Klebsiella pneumoniae
8%
Intensive Care
7%
Escherichia coli
7%
Oncology
7%
Ciprofloxacin
7%
Meningitis
7%
Influenza Vaccine
7%
Influenza A (H3N2)
6%
Antibiotics
6%
Osteomyelitis
6%
COVID-19
6%
Blood Culture
6%
Antibiotic Prophylaxis
6%
Case-Control Study
6%
Cancer
5%
Surgical Technique
5%
Neonatal Infant
5%
Selectin (Glycoprotein)
5%
Pulsed Field Gel Electrophoresis
5%
Serositis
5%
RNA 16S
5%
Adverse Outcome
5%
Infusion
5%
Multivariate Analysis
5%